BofA Cuts Teladoc Price Target to $7, Cites Mixed Segment Outlook
BofA Securities reduced its target on Teladoc Health to $7 from $7.50 while keeping a Neutral rating, citing continued uncertainty in the company’s BetterHelp and Chronic Care segments. The firm lowered its valuation multiple to 4.1x calendar year 2026 EBITDA and noted flat sequential BetterHelp user growth alongside weaker year-over-year trends. T…